Bio-Rad Laboratories, Inc. (BIO) Cash Flow Statement
Where BIO’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- $532.2M +16.9% vs 2024
- Capital expenditures
- $157.6M 6.1% of revenue
- Free cash flow
- $374.6M 14.5% margin
- Returned to shareholders
- $295.5M 79% of free cash flow
- Change in cash
- $40.3M cash at year-end $532.2M
Drawn to scale: where the cash came from and how it was used. Hover for values.
BIO operating cash flow, capex and free cash flow
BIO cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $216.1M2016 | $532.2M2025 | +10.5%/yr | |
| Capital expenditures | $141.6M2016 | $157.6M2025 | +1.2%/yr | |
| Free cash flow | $74.5M2016 | $374.6M2025 | +19.7%/yr | |
| Free cash flow margin | 3.6%2016 | 14.5%2025 | +10.9 pts | |
| Operating cash flow / net income | 8.312016 | 0.702025 | −7.61 | |
| Stock-based compensation | $19.7M2016 | $58.0M2025 | +12.7%/yr | |
| Dividends paid | $4.4M2017 | $100.10B2023 | +432.8%/yr | |
| Share buybacks (net) | $02016 | $295.5M2025 | — | |
| Capex / revenue | 6.8%2016 | 6.1%2025 | −0.7 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BIO cash flow by activity
BIO net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
BIO cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | $759.9M | −$1.84B | −$637.3M | −$3.63B | $4.25B | $3.81B | $1.76B | $365.6M | $122.2M | $26.0M |
| Depreciation & amortization | $165.4M | $151.6M | $145.9M | $137.3M | $133.8M | $138.6M | $134.2M | $138.1M | $148.7M | $142.9M |
| Stock-based compensation | $58.0M | $62.3M | $61.3M | $60.9M | $51.2M | $41.6M | $35.6M | $27.8M | $23.4M | $19.7M |
| Change in working capital | $272.4M | −$620.8M | −$432.8M | −$407.0M | $13.9M | $1.09B | $55.4M | $77.0M | −$203.7M | −$39.1M |
| Other non-cash items | −$723.5M | $2.71B | $1.24B | $4.03B | −$3.79B | −$4.50B | −$1.53B | −$323.0M | $13.5M | $66.6M |
| Cash from operating activities | $532.2M | $455.2M | $374.9M | $194.4M | $656.5M | $585.0M | $457.9M | $285.5M | $104.1M | $216.1M |
| Investing activities | ||||||||||
| Capital expenditures | −$157.6M | −$189.0M | −$156.7M | −$114.2M | −$120.8M | −$108.6M | −$98.5M | −$129.8M | −$115.1M | −$141.6M |
| Investments (net) | $186.3M | −$160.2M | −$110.5M | −$994.2M | −$538.2M | $119.6M | −$119.3M | −$68.4M | $17.1M | −$58.2M |
| Acquisitions & other investing | −$218.4M | $189.0M | $287.4M | −$99.2M | −$125.5M | −$80.9M | $8.9M | $11.3M | −$77.6M | −$14.1M |
| Cash from investing activities | −$189.7M | −$160.2M | $20.2M | −$1.21B | −$784.4M | −$69.9M | −$208.9M | −$187.0M | −$175.6M | −$213.9M |
| Financing activities | ||||||||||
| Dividends paid | — | — | −$100.10B | −$68.18B | −$35.28B | −$20.2M | −$3.83B | — | −$4.4M | — |
| Share repurchases & issuance (net) | −$295.5M | −$203.6M | −$428.7M | −$215.7M | −$50.0M | −$100.0M | −$28.0M | −$48.9M | −$2.9M | $11.3M |
| Net borrowing (repayment) | −$500,000 | −$400,000 | −$500,000 | $1.19B | −$3.0M | −$426.9M | −$1.1M | −$3.0M | −$352,000 | −$266,000 |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $12.8M | −$14.8M | $100.10B | $68.19B | $35.28B | $24.1M | $3.84B | $3.2M | $8.0M | −$2.0M |
| Cash from financing activities | −$283.2M | −$218.8M | −$425.6M | $973.6M | −$55.4M | −$523.0M | −$22.8M | −$48.7M | $341,000 | $9.0M |
| Summary | ||||||||||
| Net change in cash | $40.3M | $85.4M | −$30.2M | −$36.6M | −$196.0M | $4.5M | $228.5M | $49.2M | −$72.2M | −$1.7M |
| Cash at end of period | $532.2M | $489.8M | $404.4M | $434.5M | $471.1M | $667.1M | $662.7M | $434.2M | $385.0M | $457.2M |
| Free cash flow | $374.6M | $266.2M | $218.3M | $80.3M | $535.7M | $476.4M | $359.4M | $155.7M | −$11.0M | $74.5M |
| Free cash flow margin | 14.5% | 10.4% | 8.2% | 2.9% | 18.3% | 18.7% | 15.5% | 6.8% | −0.5% | 3.6% |
| Capex / revenue | 6.1% | 7.4% | 5.9% | 4.1% | 4.1% | 4.3% | 4.3% | 5.7% | 5.3% | 6.8% |
| Operating cash flow / net income | 0.70 | — | — | — | 0.15 | 0.15 | 0.26 | 0.78 | 0.85 | 8.31 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$13.3M | −$527.1M | $720.0M | −$341.9M | −$120.1M | $64.0M | −$715.8M | $653.2M | −$2.17B | $383.9M | $349.7M | $106.3M |
| Depreciation & amortization | $41.1M | $40.9M | $42.5M | $44.2M | −$38.1M | $38.1M | $49.3M | $38.9M | $36.4M | $37.1M | $37.2M | $37.3M |
| Stock-based compensation | $14.5M | $15.0M | $15.9M | $14.9M | −$15.3M | $15.3M | $16.4M | $15.6M | $15.0M | $15.3M | $16.2M | $15.9M |
| Change in working capital | $2.6M | −$168.5M | $254.1M | −$102.4M | −$43.6M | $43.6M | $57.0M | $220.7M | −$679.5M | $54.0M | −$8.2M | −$2.5M |
| Other non-cash items | $53.8M | $747.8M | −$867.6M | $506.1M | $333.6M | −$31.1M | $717.3M | −$764.8M | $2.89B | −$420.5M | −$313.9M | −$59.3M |
| Cash from operating activities | $98.7M | $108.1M | $164.9M | $120.9M | $116.5M | $129.9M | $124.2M | $163.6M | $97.6M | $69.8M | $81.0M | $97.7M |
| Investing activities | ||||||||||||
| Capital expenditures | −$32.0M | −$30.0M | −$45.8M | −$31.7M | −$45.7M | −$34.4M | −$42.9M | −$63.6M | −$42.3M | −$40.2M | −$42.2M | −$44.1M |
| Investments (net) | −$35.7M | −$63.3M | $11.6M | −$43.0M | −$115.4M | $2.9M | −$30.5M | −$55.6M | −$30.9M | −$43.1M | $72.2M | −$9.5M |
| Acquisitions & other investing | $1.0M | $100,000 | $0 | $31.7M | $45.7M | $34.4M | $42.9M | $63.6M | $42.3M | $40.2M | $42.2M | $44.1M |
| Cash from investing activities | −$66.7M | −$93.2M | −$34.2M | −$43.0M | −$115.4M | $2.9M | −$30.5M | −$55.6M | −$30.9M | −$43.1M | $72.2M | −$9.5M |
| Financing activities | ||||||||||||
| Dividends paid | −$15.7M | −$33.3M | — | −$62.7M | −$48.9M | — | — | −$15.8M | — | −$15.8M | −$85.44B | −$4.6M |
| Share repurchases & issuance (net) | −$31.5M | −$47.8M | −$279.7M | −$53.4M | −$140.2M | −$101.9M | −$14,000 | −$97.8M | −$101.0M | −$4.7M | −$200.0M | −$21.3M |
| Net borrowing (repayment) | −$200,000 | −$100,000 | −$200,000 | $0 | −$200,000 | −$100,000 | −$41,000 | −$100,000 | — | — | — | −$118,000 |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $19.5M | $37.2M | $283.2M | $63.6M | $53.0M | $4.3M | −$26.2M | $17.8M | $4.4M | $20.6M | $85.44B | −$512,000 |
| Cash from financing activities | −$27.9M | −$44.0M | $3.3M | −$52.5M | −$136.3M | −$97.7M | −$26.2M | −$96.0M | −$96.6M | $21,000 | −$200.6M | −$26.6M |
| Summary | ||||||||||||
| Net change in cash | $9.5M | −$23.2M | $132.0M | $26.5M | −$151.4M | $33.3M | $77.6M | $4.5M | −$26.0M | $29.4M | −$53.9M | $67.8M |
| Cash at end of period | $518.8M | $509.0M | $529.8M | $398.2M | $371.7M | $523.1M | $489.8M | $412.2M | $407.7M | $433.8M | $404.4M | $458.3M |
| Free cash flow | $66.7M | $78.1M | $119.1M | $89.2M | $70.8M | $95.5M | $81.2M | $100.0M | $55.4M | $29.6M | $38.8M | $53.6M |
| Free cash flow margin | 10.2% | 13.2% | 17.2% | 13.7% | 10.9% | 16.3% | 12.2% | 15.4% | 8.7% | 4.8% | 5.7% | 8.5% |
| Capex / revenue | 4.9% | 5.1% | 6.6% | 4.9% | 7.0% | 5.9% | 6.4% | 9.8% | 6.6% | 6.6% | 6.2% | 7.0% |
| Operating cash flow / net income | — | — | 0.23 | — | — | 2.03 | — | 0.25 | — | 0.18 | 0.23 | 0.92 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
BIO cash generation
In fiscal 2025 (ended December 31, 2025), Bio-Rad Laboratories generated $532.2 million of cash from operations (up 16.9%) and spent $157.6 million on capital expenditures, leaving free cash flow of $374.6 million, 14.5% of revenue. It returned $295.5 million to shareholders through dividends ($0) and net share buybacks ($295.5 million). Cash and equivalents rose by $40.3 million over the year.
Related: BIO income statement, BIO balance sheet. See the BIO stock overview for the latest quote and news.
BIO cash flow FAQ
What is Bio-Rad Laboratories's free cash flow?
Bio-Rad Laboratories's free cash flow was $374.6 million in fiscal 2025: $532.2 million of operating cash flow minus $157.6 million of capital expenditures It was $266.2 million a year earlier..
How much cash does Bio-Rad Laboratories generate from operations?
Bio-Rad Laboratories generated $532.2 million of cash from operating activities in fiscal 2025, 0.70 times its net income of $759.9 million.
How much does Bio-Rad Laboratories spend on capital expenditures?
Bio-Rad Laboratories spent $157.6 million on capital expenditures in fiscal 2025, 6.1% of revenue, compared with $189.0 million the year before.
How much stock does Bio-Rad Laboratories buy back?
Bio-Rad Laboratories spent $295.5 million on net share repurchases in fiscal 2025.